Patent expiries are expected to have a significant impact on the pharmaceutical industry over the next few years. Between 2026 and 2030, a large number of pharmaceutical products will lose patent protection, placing nearly USD 300 billion in revenues at risk, linked to the loss of exclusivity for around 190 products.

A meaningful share of this exposure is concentrated in a relatively small set of high-revenue therapies, making the effects of these expiries more uneven across companies. As these therapies approach expiry within a similar timeframe, the impact is likely to become more pronounced and visible.